Technology ID
TAB-3498

CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines

E-Numbers
E-002-2020-0
Lead Inventor
Ward, Michael (National Institute of Neurological Disorders and Stroke)
Co-Inventors
Kampmann, Martin (University of California, San Francisco (UCSF))
Ludwig, Connor (University of California, San Francisco (UCSF))
Tian, Rulin (University of California, San Francisco (UCSF))
Applications
Therapeutics
Research Materials
Therapeutic Areas
Neurology
Lead IC
NINDS
This invention includes human induced pluripotent stem cell (iPSC) lines that harbor a single copy dCas9-BFP-KRAB at the CLYBL safe harbor locus (mediating CRISPR inhibition of human gene expression) and/or a single copy of dox-inducible NGN2 at the AAVS1 locus (enabling the differentiation of the iPSCs into neurons). The CRISPR-mediated inhibition of human gene expression is maintained into the differentiated neurons, permitting functional studies of targeted genes in neurons.
Commercial Applications
The stem cell lines can be used for forward genetic and chemogenetic screens for drug tests of neurological diseases.

Competitive Advantages
The stem cell lines included in this technology permit direct genetic and screening approaches on neurons.
Licensing Contact:
Olufemi, Olufunmilola (Lola)
olufunmilola.olufemi@nih.gov